| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary targets of Antiproliferative agent-15 are cancer cell lines, specifically human colon cancer (HCT116 and HCT15) and brain cancer (LN-229 and GBM-10) cells. The compound shows selective activity with IC₅₀ values of 8.3 µM against HCT116 cells, 4.8 µM against HCT15 cells, 18.3 µM against LN-229 cells, and 12 µM against GBM-10 cells. Importantly, it is inactive against normal cell lines (CHO) and ovarian cancer cell lines (A2780), indicating selective antiproliferative activity.
|
|---|---|
| ln Vitro |
With IC50 values of 8.3 μM, 4.8 μM, 18.3 μM, and 12 μM, respectively, antiproliferative agent-15 (compound 6a) has antiproliferative action against human colon (HCT116 and HCT15), brain (LN-229 and GBM-10) cancer cell lines. Antiproliferative agent-15, however, is inactive against normal cell lines (CHO) and ovarian cancer cell lines (A2780)[1].
In vitro, Antiproliferative agent-15 shows antiproliferative activity against human colon cancer (HCT116 and HCT15) and brain cancer (LN-229 and GBM-10) cell lines. The IC₅₀ values are 8.3 µM for HCT116 cells, 4.8 µM for HCT15 cells, 18.3 µM for LN-229 cells, and 12 µM for GBM-10 cells. The compound is inactive against normal cell lines (CHO) and ovarian cancer cell lines (A2780), demonstrating selectivity for certain cancer types. These in vitro activities support its potential as a targeted anticancer agent. |
| ln Vivo |
Specific in vivo activity data for Antiproliferative agent-15 are not available in the consulted sources. As an anticancer agent with selective activity against colon and brain cancer cell lines, it may have potential in vivo efficacy in xenograft models of these cancers. However, no specific in vivo studies have been reported. Further research is needed to evaluate its pharmacokinetics, efficacy, and safety in animal models.
|
| Enzyme Assay |
No specific protocols for enzyme/receptor binding assays are available for Antiproliferative agent-15. As a thienopyrimidine-derived anticancer agent, it may interact with specific molecular targets involved in cell proliferation. However, the exact molecular targets have not been identified in the available literature. Standard kinase inhibition or receptor binding assays could be employed to identify its mechanism of action, but none have been reported.
|
| Cell Assay |
Cellular assays for Antiproliferative agent-15 typically involve treating cancer cell lines with the compound at various concentrations for 48-72 hours. Cell viability is assessed by MTT or SRB assays, and IC₅₀ values are calculated from dose-response curves. The cell lines used include HCT116 and HCT15 (human colon cancer) and LN-229 and GBM-10 (human brain cancer). Normal cell lines such as CHO are used as controls to assess selectivity.
|
| Animal Protocol |
In vivo animal experiments for Antiproliferative agent-15 are not detailed in the available literature. For anticancer studies, typical animal models include xenograft mouse models where colon or brain cancer cells are implanted and mice are treated with the compound. Tumor volume, body weight, and survival would be monitored. However, such studies have not been reported for this specific compound. Further research is needed to evaluate its in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Antiproliferative agent-15 are limited. With a molecular weight of 282.36 g/mol, it would be expected to have reasonable oral bioavailability. The compound is slightly soluble in DMSO. However, detailed ADME parameters including Cmax, Tmax, half-life, and bioavailability are not available in the consulted sources. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicological data for Antiproliferative agent-15 are limited. The compound's inactivity against normal cell lines (CHO) suggests it may have a favorable selectivity profile and potentially lower toxicity. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling the compound. It is intended for research use only and is not approved for human use.
|
| References |
[1]. Haneen Amawi, et al. Thienopyrimidine derivatives exert their anticancer efficacy via apoptosis induction, oxidative stress and mitotic catastrophe. Eur J Med Chem. 2017 Sep 29;138:1053-1065.
|
| Additional Infomation |
Antiproliferative agent-15 is a thienopyrimidine-derived anticancer agent with selective antiproliferative activity against human colon cancer (HCT116, HCT15) and brain cancer (LN-229, GBM-10) cell lines. It shows IC₅₀ values of 8.3 µM, 4.8 µM, 18.3 µM, and 12 µM respectively, and is inactive against normal and ovarian cancer cells. It serves as a potent experimental tool in targeted cancer research. It is not approved for any clinical indication.
|
| Molecular Formula |
C16H14N2OS
|
|---|---|
| Molecular Weight |
282.36
|
| Exact Mass |
282.083
|
| CAS # |
19819-18-2
|
| PubChem CID |
209396
|
| Appearance |
Off-white to light yellow solid powder
|
| Vapour Pressure |
2.72E-07mmHg at 25°C
|
| LogP |
3.942
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
430
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC2=C(C1)C3=C(S2)N=C(NC3=O)C4=CC=CC=C4
|
| InChi Key |
CDFWRIZOSNAGCV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2OS/c19-15-13-11-8-4-5-9-12(11)20-16(13)18-14(17-15)10-6-2-1-3-7-10/h1-3,6-7H,4-5,8-9H2,(H,17,18,19)
|
| Chemical Name |
2-phenyl-5,6,7,8-tetrahydro-3H-[1]benzothiolo[2,3-d]pyrimidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5416 mL | 17.7079 mL | 35.4158 mL | |
| 5 mM | 0.7083 mL | 3.5416 mL | 7.0832 mL | |
| 10 mM | 0.3542 mL | 1.7708 mL | 3.5416 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
